findmyKOL
Clinical trialNCT05493618WithdrawnPhase 1/PHASE2Interventional

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

SponsorHackensack Meridian HealthEnrollment0Multiple Myeloma, Refractory
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Lombardi Comprehensive Cancer Center, Georgetown University

    Washington D.C., District of Columbia, United States

  • John Theurer Cancer Center, Hackensack Meridian Health

    Hackensack, New Jersey, United States

  • Jersey Shore Medical Center

    Neptune City, New Jersey, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Belantamab mafodotin →Dexamethasone →Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2022
Primary completion
30 Nov 2025
Completion
30 Nov 2025
Last update posted
27 Jan 2023
Registered enrollment
0
Registry id
NCT05493618
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.